A molecule's right to choose: How diabetogenic class II MHC products bind peptides

1Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

The distinction between peptides that bind to class II MHC products under laboratory conditions and those that do so physiologically is important for the prediction of antigens recognized by autoreactive T cells. In this issue of the JCI, Suri et al., using antigen-presenting cells, compared the peptides that bound to human HLA-DQ8 and those that bound to mouse I-Ag7, both class II MHC products that predispose their carriers to type 1 diabetes (see the related article beginning on page 2268). The rules of engagement for the peptide ligands of the DQ8 and I-Ag7 molecules involve similarities in their anchor residues, which mediate stable interaction with class II MHC products. The peptides identified derive from overlapping sets of self proteins.

Cite

CITATION STYLE

APA

Ploegh, H. L. (2005, August). A molecule’s right to choose: How diabetogenic class II MHC products bind peptides. Journal of Clinical Investigation. https://doi.org/10.1172/JCI26018

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free